Home

Natalie Sacks

CIK 1683811 · Chief Medical Officer · last filed 2026-02-20

Natalie Sacks is a Chief Medical Officer who has filed 36 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for CRBU, was dated Feb 20, 2026. Across all open-market trades the lifetime net is −$1.4M, making them a net seller over the disclosed history. 6 SEC filings were submitted jointly with Caribou Biosciences, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

36

Lifetime Open-Market Net

-$1.37M

Filer Profile

Reported Address
C/O ADURO BIOTECH, INC.
740 HEINZ AVENUE
BERKELEY, CA 94710
Related Filers
Caribou Biosciences, Inc. — 6 joint filings, latest 2026-02-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRBU Director — $1.29 — $0 5 2026-02-20
ZYME Director — $27.50 — $0 4 2022-12-23
Harpoon Therapeutics, Inc. (HARP) Delisted Chief Medical Officer 4,575 $23.01 $105.3K -$1.27M 19 2022-02-01
CHINOOK THERAPEUTICS, INC. (ADRO) Delisted Chief Medical Officer 173,720 — — -$109.0K 8 2018-09-14

Recent Filings

36 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-02-20 CRBU Grant (A) — $0 EDGAR
2025-02-21 CRBU Grant (A) — $0 EDGAR
2024-02-22 CRBU Grant (A) — $0 EDGAR
2023-02-23 CRBU Grant (A) — $0 EDGAR
2022-12-23 ZYME Grant (A) — $0 EDGAR
2022-02-01 Harpoon Therapeutics, Inc. (HARP) Delisted Grant (A) — $0 EDGAR
2021-12-21 CRBU Grant (A) — $0 EDGAR
2021-11-15 Harpoon Therapeutics, Inc. (HARP) Delisted Grant (A) — $0 EDGAR
2021-05-07 ZYME Grant (A) — $0 EDGAR
2021-01-29 Harpoon Therapeutics, Inc. (HARP) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 36
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.